BGM
KYMR icon

Burkehill Global Management’s Kymera Therapeutics KYMR Stock Holding History

Burkehill Global Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.25M Hold
75,000
– – 0.31% 64
2025
Q4 		$5.84M Hold
75,000
– – 0.38% 70
2025
Q3 		$4.25M Hold
75,000
– – 0.24% 89
2025
Q2 		$3.27M Buy
+75,000
New +$2.58M 0.24% 73

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Burkehill Global Management's KYMR Position: Q1 2026 in Review

Burkehill Global Management held its Kymera Therapeutics (KYMR) position steady in Q1 2026 at 75,000 shares worth $6.25M. The position accounts for 0.31% of the portfolio, ranked #64.

Burkehill Global Management first reported a position in KYMR in Q2 2025 and has held it in 4 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Burkehill Global Management held 75,000 shares of Kymera Therapeutics worth $6.25M as of Q1 2026.
  • Burkehill Global Management left its Kymera Therapeutics share count unchanged in Q1 2026.
  • Kymera Therapeutics made up 0.31% of Burkehill Global Management's portfolio in Q1 2026, its #64 holding.
  • Burkehill Global Management first reported a position in Kymera Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Burkehill Global Management's 13F filing for Q1 2026, filed 15 May 2026.